Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alligator Bioscience AB (publ) (ATORX.ST)
Lund, SE
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its drug development. These include ALLIGATOR-GOLD and ALLIGATOR-FAB, an extensive human antibody library boasting roughly 60 billion distinct antibody fragments; FIND, a molecular evolution technique used for optimizing antibodies and other proteins; and RUBY, a specialized format for creating bispecific antibodies. Alligator Bioscience's pipeline features several promising candidates. In the clinical stage, Mitazalimab, an immunostimulatory CD40 antibody, has successfully completed Phase I trials for metastatic cancer. Also undergoing Phase I clinical evaluation is ATOR-1017, another immunostimulatory antibody designed to bind to the 4-1BB receptor on tumor-specific T cells. For its preclinical efforts, the company is advancing ALG.APV-527, a bispecific antibody targeting both 4-1BB and 5T4 for cancer therapy. Additionally, Alligator Bioscience holds an interest in the Biosynergy (AC101) project, which is currently in Phase I. To bolster its research and development capabilities, Alligator Bioscience has formed multiple strategic collaborations. It has a co-development partnership with Aptevo Therapeutics Inc. for ALG.APV-527, and a research alliance with MacroGenics, Inc. to create novel immunotherapies. Further collaborations include a joint research agreement with BioArctic AB (publ) to utilize proprietary antibody generation technologies for new product candidates, and a research and license agreement with Orion Corporation aimed at discovering and developing new bispecific antibody cancer therapeutics. The company was established in 2000.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.46% | +2.61% | +20.14% | +13.41% | -81.65% | -36.79% | -94.48% | -99.96% | -100.00% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-99.1% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+93.1% ★ Q1'26: +100.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-34,911.5%
-
EBIT margin Biotechnology: +0.0%-21,738.1%
-
ROIC Biotechnology: -16.1%— Q1'26: -175.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+217.0% Q1'26: +7,118.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.35× Q1'26: -0.46× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
Dec 2028 1 Rev. Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
58.24M
est: 59.67M (-2.4%)
|
56.88M
est: 7.00M (+712.5%)
|
26.96M
est: 16.73M (+61.1%)
|
4.36M
est: 11.85M (-63.2%)
|
4.35M
est: 3.05M (+42.7%)
|
12.94M
est: 9.76M (+32.6%)
|
35.70M
est: 21.45M (+66.4%)
|
58.11M
est: 45.95M (+26.4%)
|
57.77M
est: 20.85M (+177.1%)
|
514.0K
est: 12.85M (-96.0%)
|
11.90M
11.90M – 11.90M
-7.4% YoY
|
11.90M
11.90M – 11.90M
+0.0% YoY
|
23.80M
23.80M – 23.80M
+100.0% YoY
|
23.80M
23.80M – 23.80M
0.0% YoY
|
| EBITDA |
-45.80M
est: -59.67M (+23.2%)
|
-60.55M
est: -7.00M (-765.1%)
|
-144.14M
est: -16.73M (-761.6%)
|
-197.73M
est: -11.85M (-1,569.0%)
|
-131.46M
est: -3.05M (-4,210.2%)
|
-130.39M
est: -9.76M (-1,236.0%)
|
-180.99M
est: -21.45M (-743.9%)
|
-237.61M
est: -45.95M (-417.1%)
|
-165.47M
est: -20.85M (-693.6%)
|
-121.98M
est: -12.85M (-849.3%)
|
-11.90M
-11.90M – -11.90M
+7.4% YoY
|
-11.90M
-11.90M – -11.90M
+0.0% YoY
|
-23.80M
-23.80M – -23.80M
-100.0% YoY
|
-23.80M
-23.80M – -23.80M
+0.0% YoY
|
| EBIT |
-48.35M
est: -59.67M (+19.0%)
|
-63.74M
est: -7.00M (-810.6%)
|
-150.04M
est: -16.73M (-796.8%)
|
-209.69M
est: -11.85M (-1,669.9%)
|
-142.98M
est: -3.05M (-4,588.0%)
|
-141.50M
est: -9.76M (-1,349.8%)
|
-192.76M
est: -21.45M (-798.8%)
|
-248.10M
est: -45.95M (-439.9%)
|
-214.20M
est: -20.85M (-927.3%)
|
-111.73M
est: -12.85M (-769.5%)
|
-11.90M
-11.90M – -11.90M
+7.4% YoY
|
-11.90M
-11.90M – -11.90M
+0.0% YoY
|
-23.80M
-23.80M – -23.80M
-100.0% YoY
|
-23.80M
-23.80M – -23.80M
+0.0% YoY
|
| Net Income |
-48.36M
est: -65.97M (+26.7%)
|
-63.76M
est: -156.08M (+59.1%)
|
-150.04M
est: -240.02M (+37.5%)
|
-210.53M
est: -322.06M (+34.6%)
|
-143.61M
est: -217.43M (+34.0%)
|
-141.74M
est: -194.73M (+27.2%)
|
-193.40M
est: -105.59M (-83.2%)
|
-248.59M
est: -9.72M (-2,457.6%)
|
-233.89M
est: -170.80M (-36.9%)
|
-51.35M
est: -53.86M (+4.7%)
|
-48.09M
-48.09M – -48.09M
+10.7% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
—
— – —
|
| SGA |
23.47M
est: 64.15M (-63.4%)
|
18.61M
est: 7.53M (+147.3%)
|
18.24M
est: 17.99M (+1.4%)
|
13.36M
est: 12.74M (+4.9%)
|
13.22M
est: 3.28M (+303.1%)
|
18.94M
est: 10.49M (+80.5%)
|
31.21M
est: 23.06M (+35.4%)
|
—
est: -1.62B (+100.0%)
|
—
est: -734.89M (+100.0%)
|
-91.79M
est: -452.92M (+79.7%)
|
-419.43M
-419.43M – -419.43M
+7.4% YoY
|
-419.43M
-419.43M – -419.43M
+0.0% YoY
|
-838.86M
-838.86M – -838.86M
-100.0% YoY
|
-838.69M
-838.69M – -838.69M
+0.0% YoY
|
| EPS |
-0.80
est: -7.60 (+89.5%)
|
-0.89
est: -17.97 (+95.0%)
|
-2.10
est: -27.64 (+92.4%)
|
-2.94
est: -37.08 (+92.1%)
|
-2.01
est: -25.04 (+92.0%)
|
-1.47
est: -22.42 (+93.4%)
|
-0.88
est: -12.16 (+92.8%)
|
-46.50
est: -0.35 (-13,069.4%)
|
-26.93
est: -6.20 (-334.0%)
|
-1.87
est: -1.96 (+4.4%)
|
-1.75
-1.75 – -1.75
+10.7% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Søren Bregenholt | Chief Executive Officer | 6M | male |
| Greta Eklund | Investor Relations & Communications Manager | — | female |
| Johan Gileus | Chief Financial Officer | — | male |
| Tom Moore | Chief Medical Officer | — | — |
| Yago Pico de Coana | Medical Science Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ATORX.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
